CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. ROYALTY INTEREST ACQUISITION AGREEMENT Dated as of April 22, 2016 between Aviragen Therapeutics, Inc., Biota...Royalty Interest Acquisition Agreement • April 26th, 2016 • Aviragen Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This ROYALTY INTEREST ACQUISITION AGREEMENT is made and entered into as of April 22, 2016 by and between Aviragen Therapeutics, Inc. (formerly known as Biota Pharmaceuticals, Inc.), a Delaware corporation (“Aviragen”), Biota Holdings Pty Ltd (formerly known as Biota Holdings Limited), a corporation organized and existing under the laws of Victoria, Australia (“BHPL”), Biota Scientific Management Pty. Ltd., a corporation organized and existing under the laws of Victoria, Australia (“BSM”), and HealthCare Royalty Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (the “Agreement”).
ContractProtective Rights Agreement • April 26th, 2016 • Aviragen Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
